AI assistant
Marker Therapeutics, Inc. — Director's Dealing 2018
Dec 28, 2018
35150_dirs_2018-12-28_a302d1b6-47a6-4cf0-8232-7961c61476f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-12-21
Reporting Person: Leen Ann M. (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1993059 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants to Acquire Common Stock | $2.99 | 2023-10-17 | Common Stock (722783) | Direct | |
| Employee Stock Option (Right to Buy) | $9.18 | 2028-10-19 | Common Stock (500000) | Direct |
Footnotes
F1: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, that were granted in connection with entering into a consulting agreement with the Company to serve as the Company's Chief Scientific Officer. One quarter of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal monthly installments over a three year period upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.